Ionis Provides Updates of ION449 in P-IIb (SOLANO) Study for the Treatment of Hypercholesterolemia
Shots:
- The P-IIb (SOLANO) study evaluates the efficacy, safety, and tolerability of ION449 (60mg) vs PBO in 411 patients with hyperlipidemia LDL-C ≥70 mg/dL and <190mg/dL on maximum tolerated statin & ezetimibe
- The trial met its 1EPs i.e., the therapy showed a 62.3% reduction in low-density lipoprotein cholesterol (LDL-C) levels @28wks., was safe and well tolerated. Additionally, the therapy will not advance into P-III development, based on the pre-specified efficacy criteria
- The therapy has been developed by using the LICA technology platform that helps to reduce plasma levels of proprotein convertase subtilisin/Kexin type 9 (PCSK9)
Ref: PRNewswire | Image: Ionis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
